The Impact of Coronary Ischemia Assessment on Outcomes in Those With Scar‐Dependent Ventricular Tachycardia

Figures

• 

  Figure 1. Kaplan–Meier survival curve for patients presenting with monomorphic VT with structural heart disease. The endpoint was 12‐month freedom from VT recurrence, ICD therapies, heart failure hospitalization, and death. Freedom from the primary endpoint at 12 months was 55.8% (± 4.5%).

• 

  Central Illustration 1. In those presenting with monomorphic VT, undergoing coronary ischaemia assessment was associated with improved 12‐month event‐free survival from the primary endpoint of VT recurrence, ICD therapy, heart failure hospitalisation and death.

• 

  Figure 2. Kaplan–Meier survival curves demonstrating 12‐month event‐free survival from VT recurrence, ICD therapy, heart failure hospitalization and death. (A) Comparison of those with and without an ischemia assessment shows improved event‐free survival of those undergoing ischemia assessment. (B) Comparison of ischemic versus nonischaemic cardiomyopathy shows no significant difference in outcomes at 12 months. (C) Comparison of none, mild, moderate, or severe coronary disease shows a trend towards worse outcomes with more severe coronary disease. (D) Comparison of coronary intervention versus no coronary intervention shows improved event‐free survival in those undergoing intervention.

• 

  Figure 3. Kaplan–Meier survival curves demonstrating secondary outcomes at 12 months, stratified by presence of an ischemia assessment. (A) Recurrent ventricular arrhythmia/appropriate ICD therapy was similar between those who did and did not undergo an ischemia assessment. (B) Heart failure hospitalization was also similar between the two groups. (C) All‐cause mortality was significantly lower in the ischemia assessment group (98.3%) versus those not undergoing ischemia assessment (86.5%) (p < 0.01).

• 

  Figure 4. Kaplan–Meier survival curves demonstrating 12‐month event‐free survival comparing those with and without an ischemia assessment by etiology (ICM vs NICM). Amongst those with ICM, 12‐month event‐free survival was 63.4% for those who had an IA versus 34.4% for those who did not, p = 0.003). In the NICM cohort, 12‐month event‐free survival was 78.9% for those undergoing IA versus 53.6% for those who did not have an IA, p = 0.009.